/
CODX
$2.98-$0.08 (-2.61%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$11.3M
4M shares
52-week range
$1.26 – $46.50
4% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
183.56%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-246.32
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39.9K | $215.0K | $74.6M | $97.9M | $34.2M | $6.8M | $3.9M | $622.5K |
| Cost of revenue | $9.4K | $112.4K | $16.6M | $11.6M | $5.5M | $4.2M | $999.1K | $222.4K |
| Gross profit | $30.5K | $102.5K | $58.0M | $86.3M | $28.7M | $2.6M | $2.9M | $400.1K |
| Gross margin | 76.5% | 47.7% | 77.7% | 88.2% | 84.0% | 38.6% | 74.5% | 64.3% |
| R&D | $1.4M | $1.4M | $3.2M | $15.0M | $17.4M | $23.0M | $21.0M | $19.1M |
| Operating income | −$6.1M | −$5.9M | $41.7M | $46.1M | −$27.0M | −$42.7M | −$40.1M | −$31.3M |
| EBITDA | −$6.1M | −$6.0M | $41.8M | $46.0M | −$10.3M | −$36.9M | −$36.2M | −$47.4M |
| Net income | −$6.3M | −$6.2M | $42.5M | $36.7M | −$14.2M | −$35.3M | −$37.6M | −$46.9M |
| Net margin | -15714.3% | -2882.0% | 57.0% | 37.5% | -41.6% | -518.7% | -961.4% | -7533.6% |
| EPS (diluted) | -15.00 | -11.09 | 1.52 | 36.90 | -13.57 | -36.00 | -37.20 | -35.25 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $552400 | $-12.15 | $-12.15–$-12.15 | 1 |
| 2027 | $17M | $-12.00 | $-12.00–$-12.00 | 1 |
| 2028 | $59M | $-6.90 | $-6.90–$-6.90 | 1 |
| 2029 | $137M | $6.60 | $6.60–$6.60 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$7.45
Price
$2.98
Implied upside
+150%
Peer comparison
Co-Diagnostics, Inc. Common Stock
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
www.codiagnostics.com- Employees
- 115
- IPO / List date
- Jul 12, 2017
- HQ
- SALT LAKE CITY, UT
Held by traders on TradeandTell
No one on the platform currently holds CODX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CODX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-01-02 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded CODX yet.
